Ovid Therapeutics Inc
NASDAQ:OVID

Watchlist Manager
Ovid Therapeutics Inc Logo
Ovid Therapeutics Inc
NASDAQ:OVID
Watchlist
Price: 1.24 USD -8.82% Market Closed
Market Cap: 88m USD
Have any thoughts about
Ovid Therapeutics Inc?
Write Note

Intrinsic Value

OVID's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one OVID stock under the Base Case scenario is 5.36 USD. Compared to the current market price of 1.24 USD, Ovid Therapeutics Inc is Undervalued by 77%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OVID Intrinsic Value
5.36 USD
Undervaluation 77%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ovid Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for OVID cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about OVID?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Ovid Therapeutics Inc

Provide an overview of the primary business activities
of Ovid Therapeutics Inc.

What unique competitive advantages
does Ovid Therapeutics Inc hold over its rivals?

What risks and challenges
does Ovid Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Ovid Therapeutics Inc recently?

Summarize the latest earnings call
of Ovid Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ovid Therapeutics Inc.

Provide P/S
for Ovid Therapeutics Inc.

Provide P/E
for Ovid Therapeutics Inc.

Provide P/OCF
for Ovid Therapeutics Inc.

Provide P/FCFE
for Ovid Therapeutics Inc.

Provide P/B
for Ovid Therapeutics Inc.

Provide EV/S
for Ovid Therapeutics Inc.

Provide EV/GP
for Ovid Therapeutics Inc.

Provide EV/EBITDA
for Ovid Therapeutics Inc.

Provide EV/EBIT
for Ovid Therapeutics Inc.

Provide EV/OCF
for Ovid Therapeutics Inc.

Provide EV/FCFF
for Ovid Therapeutics Inc.

Provide EV/IC
for Ovid Therapeutics Inc.

Show me price targets
for Ovid Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Ovid Therapeutics Inc?

How accurate were the past Revenue estimates
for Ovid Therapeutics Inc?

What are the Net Income projections
for Ovid Therapeutics Inc?

How accurate were the past Net Income estimates
for Ovid Therapeutics Inc?

What are the EPS projections
for Ovid Therapeutics Inc?

How accurate were the past EPS estimates
for Ovid Therapeutics Inc?

What are the EBIT projections
for Ovid Therapeutics Inc?

How accurate were the past EBIT estimates
for Ovid Therapeutics Inc?

Compare the revenue forecasts
for Ovid Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ovid Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ovid Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ovid Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Ovid Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ovid Therapeutics Inc with its peers.

Analyze the financial leverage
of Ovid Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Ovid Therapeutics Inc.

Provide ROE
for Ovid Therapeutics Inc.

Provide ROA
for Ovid Therapeutics Inc.

Provide ROIC
for Ovid Therapeutics Inc.

Provide ROCE
for Ovid Therapeutics Inc.

Provide Gross Margin
for Ovid Therapeutics Inc.

Provide Operating Margin
for Ovid Therapeutics Inc.

Provide Net Margin
for Ovid Therapeutics Inc.

Provide FCF Margin
for Ovid Therapeutics Inc.

Show all solvency ratios
for Ovid Therapeutics Inc.

Provide D/E Ratio
for Ovid Therapeutics Inc.

Provide D/A Ratio
for Ovid Therapeutics Inc.

Provide Interest Coverage Ratio
for Ovid Therapeutics Inc.

Provide Altman Z-Score Ratio
for Ovid Therapeutics Inc.

Provide Quick Ratio
for Ovid Therapeutics Inc.

Provide Current Ratio
for Ovid Therapeutics Inc.

Provide Cash Ratio
for Ovid Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Ovid Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Ovid Therapeutics Inc?

What is the current Free Cash Flow
of Ovid Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ovid Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ovid Therapeutics Inc

Current Assets 80.9m
Cash & Short-Term Investments 77m
Other Current Assets 3.9m
Non-Current Assets 37.2m
Long-Term Investments 21.1m
PP&E 14m
Intangibles 219k
Other Non-Current Assets 2m
Current Liabilities 14.1m
Accounts Payable 4.7m
Accrued Liabilities 9.4m
Non-Current Liabilities 15.1m
Other Non-Current Liabilities 15.1m
Efficiency

Earnings Waterfall
Ovid Therapeutics Inc

Revenue
558.6k USD
Operating Expenses
-68.7m USD
Operating Income
-68.1m USD
Other Expenses
38.3m USD
Net Income
-29.8m USD

Free Cash Flow Analysis
Ovid Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

OVID Profitability Score
Profitability Due Diligence

Ovid Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Declining ROE
Declining ROIC
20/100
Profitability
Score

Ovid Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

OVID Solvency Score
Solvency Due Diligence

Ovid Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Ovid Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OVID Price Targets Summary
Ovid Therapeutics Inc

Wall Street analysts forecast OVID stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OVID is 3.33 USD with a low forecast of 1.31 USD and a high forecast of 5.25 USD.

Lowest
Price Target
1.31 USD
6% Upside
Average
Price Target
3.33 USD
168% Upside
Highest
Price Target
5.25 USD
323% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for OVID?

Click here to dive deeper.

Dividends

Ovid Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for OVID is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

OVID Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

OVID News

Other Videos

Profile

Ovid Therapeutics Inc Logo
Ovid Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

88m USD

Dividend Yield

0%

Description

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2017-05-05. The firm is focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. The Company’s programs include OV329 (GABA aminotransferase inhibitor), OV350, OV882, and OV815 and OV825. OV329 (GABA aminotransferase inhibitor) is a next-generation GABA aminotransferase inhibitor being developed for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV329 functions by substantially reducing the activity of GABA aminotransferase (GABA-AT), a key enzyme responsible for the degradation of the brain’s major inhibitory neurotransmitter, GABA. OV350 is a small molecule that directly activates the KCC2 transporter, which is an important channel in seizure control. OV882, which is a short hairpin RNA (shRNA-551) for Angelman syndrome. OV815, which is a genetic therapy approach for KIF1A-associated neurological disorders.

Contact

NEW YORK
New York City
1460 Broadway Ste 15044
+16466617661.0
www.ovidrx.com

IPO

2017-05-05

Employees

44

Officers

CEO & Chairman
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Chief Business and Financial Officer
Mr. Jeffrey A. Rona
President & COO
Ms. Meg Alexander
Senior Vice President of Global Manufacturing & CMC QA
Dr. Dirk Haasner
Senior Vice President of Clinical Development
Dr. Julia Tsai Ph.D.
Head of Epilepsy Research
Dr. Toshiya Nishi D.V.M.
Show More
Chief Scientific Officer
Mr. Zhong Zhong Ph.D.
Vice President of Research and Early Development
Mr. Tom Parry
Show Less

See Also

Discover More
What is the Intrinsic Value of one OVID stock?

The intrinsic value of one OVID stock under the Base Case scenario is 5.36 USD.

Is OVID stock undervalued or overvalued?

Compared to the current market price of 1.24 USD, Ovid Therapeutics Inc is Undervalued by 77%.

Back to Top